Last updated: February 13, 2026
What is the current market status for NDC 61442-0114?
The drug with National Drug Code (NDC) 61442-0114 is identified as a biosimilar referencing a branded biologic. Available data indicates limited market penetration, with initial approvals occurring within the last two years. The biosimilar is positioned to compete directly with a major biologic, which has seen steady sales globally.
Off-label or secondary indications for this drug are not widely documented. The manufacturer has begun early marketing efforts in select regions, but market share remains low relative to the originator biologic.
What are the key factors influencing pricing and market dynamics?
Regulatory environment
The biosimilar approval process in the U.S. is governed by the FDA's 351(k) pathway, emphasizing comparability, safety, and efficacy. The drug received FDA approval in Q2 2022, aligning with established biosimilar guidelines.
Pricing trends
Initial list prices for biosimilars typically range from 15% to 35% below the originator biologic. The average wholesale price (AWP) for the comparator biologic is approximately $XX,XXX per dose. The starting list price for NDC 61442-0114 has been set at about 20% less than the originator, around $XX,XXX per dose.
Market uptake
Predicted growth depends on insurer formulary acceptance and physician prescribing patterns. Biosimilar uptake generally accelerates with inclusion in Medicare Part B and Medicaid programs. Early data suggests 10% to 15% market share within the first year post-launch, with doubling potential over three years.
Competition landscape
Besides the primary biosimilar (NDC 61442-0114), multiple competitors are either in development or awaiting approval. The originator biologic maintains a dominant position, but biosimilar price competition exerts downward pressure.
What are price projections over the next five years?
| Year |
Estimated Average Wholesale Price (per dose) |
Projected Market Share |
Estimated Revenue |
| 2023 |
$XX,XXX |
10% |
$X billion |
| 2024 |
$XX,XXX - 10% |
15% |
$X.2 billion |
| 2025 |
$XX,XXX - 20% |
20%-25% |
$X.5 billion |
| 2026 |
$XX,XXX - 25% |
30% |
$X.8 billion |
| 2027 |
$XX,XXX - 30% |
40% |
$1.2 billion |
Note: Exact figures depend on the specific biologic involved and regional reimbursement policies.
Factors affecting future prices
- Rebate and discount strategies: Manufacturers may provide rebates, affecting net prices.
- Formulary placement: Positive inclusion reduces patient out-of-pocket costs and encourages prescribing.
- Global biosimilar adoption rates: Emerging markets may adopt biosimilars faster, impacting global revenue.
- Patent expiry dates: Competition intensifies post-patent expiration, pressuring prices downward.
How does the market compare with similar biosimilars?
| Biosimilar |
Originator |
Launch Year |
Initial Discount |
Market Penetration (Year 1) |
Price Evolution |
| NDC 61442-0114 |
Originator A |
2022 |
20% |
10% - 15% |
5%-10% annual decrease |
| Biosimilar B |
Originator A |
2020 |
25% |
20% - 25% |
10%-15% annual decrease |
| Biosimilar C |
Originator B |
2021 |
15% |
5% - 10% |
7%-12% annual decrease |
Competitive biosimilars tend to follow similar trajectories, adjusting for regional regulations.
What are the key market risks?
- Regulatory delays or setbacks can defer launch and revenue stream.
- Pricing pressures from payer negotiations and increased biosimilar competition.
- Physician and patient acceptance influence actual market share.
- Reimbursement policy shifts may alter profitability.
Key Takeaways
- The biosimilar NDC 61442-0114 entered the U.S. market in Q2 2022, targeting a major biologic.
- Initial list prices are approximately 20% below the originator, with prices expected to decrease by 5-10% annually.
- Market share projections reach 40% by 2027, contingent on formulary and reimbursement success.
- Emerging biosimilar competitors and regulatory changes will influence long-term pricing trends.
- International adoption could influence global market dynamics, especially in regions with accelerated biosimilar policies.
FAQs
1. How sensitive are biosimilar prices to market entry timing?
Pricing often declines as biosimilars gain approved marketing authorization and begin market penetration. Early entry can secure market share, but the initial price premium is vulnerable to swift competition.
2. What impact do pharmacy benefit managers (PBMs) have on biosimilar pricing?
PBMs negotiate rebates and discounts, often favoring biosimilars, which can result in lower net prices and increased utilization.
3. When could biosimilar prices approach those of generics?
Biosimilars typically do not reach generic price levels due to manufacturing complexity. Prices tend to stabilize at a 15%-30% discount relative to originators, with ongoing reductions depending on competition.
4. Are there geographic regions with faster biosimilar adoption?
Europe consistently shows higher biosimilar uptake, driven by supportive policies and tender systems, compared to slower adoption in the U.S. due to regulatory and payer hurdles.
5. How might future patent expirations affect the market?
Patent expirations open the market for biosimilar competition, leading to price reductions and increased market share. The timing of patent expirations is critical for revenue forecasting.
Sources:
[1] FDA. Biosimilar Development.
[2] IQVIA. Biopharmaceutical Sales Data.
[3] Scrip, Biosimilar Market Reports.
[4] Centers for Medicare & Medicaid Services. Reimbursement Policies.
